- ISIN
- US28036F1057
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 26, 2021
Highlights
- Market Cap
- $3.91B
- Enterprise Value
- $3.88B
- EPS (TTM)
- -$1.67
- EBITDA (TTM)
- -$188.16M
- Year Range
- $12.15 - $40.77
- Target Price
- $42.00
- ROA (TTM)
- -33.94%
- ROE (TTM)
- -35.69%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
EWTX Performance Chart
Edgewise Therapeutics Inc (EWTX) is up 47.1% since the beginning of the year. At $37 per share, EWTX is trading 10.5% below its 52-week high of $41. Investors who bought $1,000 worth of EWTX shares 5 years ago would now be looking at an investment worth $1,430.
Loading charts...
Returns By Period
Edgewise Therapeutics Inc (EWTX) has returned 47.09% so far this year and 155.24% over the past 12 months.
Edgewise Therapeutics Inc
- 1D
- -0.84%
- 1M
- 11.62%
- YTD
- 47.09%
- 6M
- 74.31%
- 1Y
- 155.24%
- 3Y*
- 68.72%
- 5Y*
- 7.42%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
EWTX Monthly Returns History
Based on dividend-adjusted daily data since Mar 26, 2021, EWTX's average daily return is +0.15%, while the average monthly return is +2.17%. At this rate, an investment would double in approximately 2.7 years.
Historically, 45% of months were positive and 55% were negative. The best month was Dec 2023 with a return of +79.9%, while the worst month was Mar 2023 at -30.4%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, EWTX closed higher 49% of trading days. The best single day was Sep 19, 2024 with a return of +54.7%, while the worst single day was Sep 13, 2022 at -24.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 13.44% | 8.13% | 3.48% | -1.71% | 10.34% | 6.85% | 47.09% | ||||||
| 2025 | 4.94% | -6.60% | -15.93% | -25.45% | -12.93% | -8.19% | 8.77% | 0.63% | 13.03% | 12.70% | 42.45% | -4.70% | -7.06% |
| 2024 | 62.98% | -8.41% | 11.70% | -1.64% | -4.52% | 5.14% | -5.44% | 10.10% | 42.35% | 25.78% | -1.70% | -19.09% | 144.06% |
| 2023 | 14.43% | -6.35% | -30.38% | 31.48% | 15.39% | -23.42% | -5.94% | -14.27% | -8.32% | 11.69% | -5.00% | 79.93% | 22.37% |
| 2022 | -10.99% | -13.31% | -17.73% | -17.73% | -21.68% | 27.36% | 21.48% | 4.24% | -2.38% | -3.35% | -5.89% | -0.11% | -41.49% |
| 2021 | 20.37% | -11.88% | 0.80% | -26.12% | -17.91% | -9.54% | 4.80% | -0.60% | 5.58% | -12.28% | -43.41% |
Benchmark Metrics
Edgewise Therapeutics Inc has an annualized alpha of 19.96%, beta of 1.39, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since March 26, 2021.
- This stock participated in 82.92% of S&P 500 Index downside but only 60.26% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 19.96%
- Beta
- 1.39
- R²
- 0.08
- Upside Capture
- 60.26%
- Downside Capture
- 82.92%
Return for Risk
Risk / Return Rank
EWTX ranks 91 for risk / return — in the top 91% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Edgewise Therapeutics Inc (EWTX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| EWTX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.07 | ||
| Sortino ratioReturn per unit of downside risk | +0.31 | ||
| Omega ratioGain probability vs. loss probability | 1.36 | 1.37 | 0.00 |
| Calmar ratioReturn relative to maximum drawdown | 7.98 | 2.78 | +5.19 |
| Martin ratioReturn relative to average drawdown | 20.00 | 12.44 | +7.57 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Edgewise Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Edgewise Therapeutics Inc was 84.69%, occurring on Nov 10, 2023. Recovery took 248 trading sessions.
The current Edgewise Therapeutics Inc drawdown is 9.34%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -84.69%Nov 2023 | 2y 7mo | 12mo 2d | 3y 7moMar 2021 - Nov 2024 |
2025 selloff2025 | -68.81%Apr 2025 | 5mo 5d | 1y 24d | 1y 5moNov 2024 - May 2026 |
2026 correction2026 | -18.23%Jun 2026 | 8d | — | 21d 10hJun 2026 - now |
2026 correction2026 | -17.31%May 2026 | 13d | 13d | 26dMay 2026 - Jun 2026 |
Drawdown Indicators
| EWTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -84.69% | -56.78% | -27.91% |
Max Drawdown (1Y)Largest decline over 1 year | -19.59% | -9.10% | -10.49% |
Max Drawdown (3Y)Largest decline over 3 years | -68.81% | -18.90% | -49.91% |
Max Drawdown (5Y)Largest decline over 5 years | -77.95% | -25.43% | -52.52% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -9.34% | -1.80% | -7.54% |
Average DrawdownAverage peak-to-trough decline | -53.31% | -10.71% | -42.60% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.79% | 2.03% | +5.76% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Edgewise Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Edgewise Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for EWTX in comparison with other companies in the Biotechnology industry. Currently, EWTX has a P/B value of 7.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with EWTX
Add Edgewise Therapeutics Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with EWTX